Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers

Published:2012-04-04 Issue:5 Volume:91 Page:881-888
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Dooley K E,Bliven-Sizemore E E,Weiner M,Lu Y,Nuermberger E L,Hubbard W C,Fuchs E J,Melia M T,Burman W J,Dorman S E

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex

2. Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model

3. Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?

4. Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient Mice

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in tuberculosis;European Journal of Clinical Pharmacology;2024-09-06

2. Chapitre 10: Le traitement de la tuberculose active chez les populations particulières;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02

3. An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions;Medicinal Chemistry;2023-10-05

4. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs;European Respiratory Journal;2023-06-15

5. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial;BMC Infectious Diseases;2023-05-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3